Ulipristal Acetate Prior to Surgery for Endometriosis
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Selective progesterone receptor modulators may have a role in the treatment of endometriosis. The aim of this report is to review the effect of ulipristal acetate (UPA) on endometriosis lesions and symptoms in women treated prior to surgery. A pathology review of eutopic endometrium and endometriotic lesions was conducted by two gynecologic pathologists. The main outcome measures reported are pain reduction, amenorrhea, and pathologic progesterone receptor modulator-associated endometrial changes (PAECs). Overall, fifteen women with endometriosis received UPA over a 27-month study period. UPA was administered in an intermittent fashion in the majority of patients while 27% of patients had continuous treatment, between 6 and 24 months. Eleven (73%) patients reported amenorrhea on UPA and 11 (92%) of 12 patients with pain reported pain reduction or resolution. Fourteen patients (93%) proceeded with surgical management. Thirteen (93%) patients underwent excision of suspected endometriosis at surgery. Twelve cases (86%) had concurrent eutopic endometrium specimens and PAEC was identified in 58% (n = 7). Among the 14 cases that underwent surgery, a total of 49 extraovarian sites were sampled. Endometriosis was definitively identified in 31 (63%) of these sites. Three cases (21%) showed morphologic features similar to PAEC within foci of endometriosis. All cases of PAEC-like features in endometriosis also had PAEC in the endometrium. These patients had all noted pain reduction and amenorrhea preoperatively. In conclusion, PAECs may be found in endometriosis lesions in patients treated with UPA. Further prospective investigation is required to evaluate the efficacy and safety of SPRMs in women with endometriosis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In 58% of cases progesterone receptor modulator-associated endometrial changes (PAECs) were observed in both eutopic endometrium and ectopic lesions; those cases reported all pain reduction and amenorrhea [269].”
From Hormonal treatments for endometriosis: The endocrine background (2022) · cites this paper as [269]
Citations
Cites
Bulun, S. E. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0804690 · Cited by 1,772
Ulipristal Acetate versus Placebo for Fibroid Treatment before Surgery
Donnez, J., Tatarchuk, T. F., Bouchard, P., Puscasiu, L., Zakharenko, N. F., Ivanova, T., Ugocsai, G., Mara, M., Jilla, M. P., Bestel, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1103182 · Cited by 680 · cited 2×
“To date, PAECs appear to be benign and reversible in eutopic endometrium [1, 3, 11, 13].”
BackgroundUlipristal Acetate versus Leuprolide Acetate for Uterine Fibroids
Donnez, J., Tomaszewski, J., Vázquez, F., Bouchard, P., Lemieszczuk, B., Baró, F., Nouri, K., Selvaggi, L., Sodowski, K., Bestel, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1103180 · Cited by 607
Long-term treatment of uterine fibroids with ulipristal acetate☆
Donnez, J., Vázquez, F., Tomaszewski, J., Nouri, K., Bouchard, P., Fauser, B. C. J. M., Barlow, D. H., Palacios, S., Donnez, O., Bestel, E., et al. (2014) · Fertility and Sterility · doi:10.1016/j.fertnstert.2014.02.008 · Cited by 332 · cited 2×
“To date, PAECs appear to be benign and reversible in eutopic endometrium [1, 3, 11, 13].”
BackgroundWilliams, A. R. W., Bergeron, C., Barlow, D. H., & Ferenczy, A. (2012) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0b013e318251035b · Cited by 157 · cited 2×
“To date, PAECs appear to be benign and reversible in eutopic endometrium [1, 3, 11, 13].”
BackgroundSurgery for endometriosis: beyond medical therapies
Singh, S. S., & Suen, M. W. H. (2017) · Fertility and Sterility · doi:10.1016/j.fertnstert.2017.01.001 · Cited by 121 · cited 1×
“It is also important to note that while excision of endometriosis in expert hands will debulk visualized disease in many patients, it is very unlikely that all disease will be excised and hence remnant/persistent lesions may exist [20].”
BackgroundSelf-citationHormonal therapy for endometriosis: from molecular research to bedside
Tosti, C., Biscione, A., Morgante, G., Bifulco, G., Luisi, S., & Petraglia, F. (2017) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2016.05.032 · Cited by 96 · cited 1×
“Although some SPRMs may reduce bleeding and pain in patients with endometriosis [9, 10], the mechanism of action of UPA in endometriosis is not clear, and histomorphological changes in tissue affected by UPA have not been studied in any context except the eutopic endometrium of patients with uterine leiomyomata [11] a…”
BackgroundIs it time for a paradigm shift in drug research and development in endometriosis/adenomyosis?
Guo, S.-W., & Groothuis, P. G. (2018) · Human Reproduction Update · doi:10.1093/humupd/dmy020 · Cited by 95 · cited 1×
“Several attempts at studying this class of medication for endometriosis have been attempted without any clear indications that there will be a therapy to market in the near future [21].”
BackgroundProgesterone receptor modulators for endometriosis
Fu, J., Song, H., Zhou, M., Zhu, H., Wang, Y., Chen, H., & Huang, W. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009881.pub2 · Cited by 61 · cited 1×
“Although some SPRMs may reduce bleeding and pain in patients with endometriosis [9, 10], the mechanism of action of UPA in endometriosis is not clear, and histomorphological changes in tissue affected by UPA have not been studied in any context except the eutopic endometrium of patients with uterine leiomyomata [11] a…”
BackgroundDonnez, J., Arriagada, P., Marciniak, M., & Larrey, D. (2018) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1550070 · Cited by 59 · cited 3×
“During the study period, the Health Canada-approved indication for UPA was for the management of “symptomatic uterine fibroids” including the use of long-term intermittent courses.”
BackgroundInfluential
Research works printed but not linked: 2
- Bulun S. Ulipristal acetate for treatment of endometriosis-related pelvic pain. [Phase IV clinical trial]. In press Active.
- Bayer. Assess safety and efficacy of vilaprisan in subjects with endometriosis (VILLENDO). [Phase II clinical trial]. In press Active.
Cited by
Hormonal treatments for endometriosis: The endocrine background
Vannuccini, S., Clemenza, S., Rossi, M., & Petraglia, F. (2022) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-021-09666-w · Cited by 336
Novel pharmacological therapies for the treatment of endometriosis
Buggio, L., Dridi, D., Barbàra, G., Merli, C. E. M., Cetera, G. E., & Vercellini, P. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2117155 · Cited by 46
“Thus, the natural history of PAECs in endometriosis foci will be difficult to assess without exposing patients to repetitive surgical interventions [49].”
BackgroundInfluentialEkbbal, R., Jaiswal, A. K., Aggarwal, M., Singh, M., Ali, S. A., Ali, S., & Gautam, G. (2023) · Natural Resources for Human Health · doi:10.53365/nrfhh/174668 · Cited by 28
“They suppress the production of various cytokines and chemokines, thereby reducing immune cell recruitment and activation in endometriotic lesions (Chwalisz et al., 2005; Singh et al., 2020; Whitaker et al., 2014).”
BackgroundCurrent and emerging therapies for endometriosis-associated pain: a review
Tijani, E. O., Ajayi, L. O., Tijani, O. S., Akano, O. P., & Ajayi, A. F. (2025) · Middle East Fertility Society Journal · doi:10.1186/s43043-025-00221-0 · Cited by 18
“Clinical trials show SPRMs are effective in managing pain and controlling lesions, but safety concerns about endometrial hyperplasia require further study [54, 70].”
Progesterone receptor ligands for the treatment of endometriosis
Clemenza, S., Capezzuoli, T., Eren, E., GARCIA, J. M. G., Vannuccini, S., & Petraglia, F. (2022) · Minerva Obstetrics and Gynecology · doi:10.23736/s2724-606x.22.05157-0 · Cited by 13
Metadata
- Authors
- Singh, S. S., Evans, D., McDonald, S., Senterman, M., & Strickland, S.
- Affiliations
- University of Ottawa (CA)
- University of Manitoba (CA)
- Corresponding author
- Singh, Sukhbir S.
- Venue
- Reproductive Sciences
- Published
- 2020-01-31
- Volume
- 27
- Issue
- 9
- Pages
- 1707-1714
- ISSN
- 1933-7191 (ISSN-L)
- 1933-7205
- OpenAlex
- W3006040240
- Cited by
- 10
- References
- 16
- Citations by year
- 2025: 1 · 2024: 1 · 2023: 2 · 2022: 5 · 2021: 1
- FWCI
- 1.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Reproductive Sciences (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
- Health Sciences › Medicine › Obstetrics and Gynecology › Ectopic Pregnancy Diagnosis and Management
- Health Sciences › Medicine › Obstetrics and Gynecology › Gynecological conditions and treatments
- Keywords
- ulipristal acetate, endometriosis, selective progesterone receptor modulators, preoperative treatment, eutopic endometrium, endometriosis excision, dysmenorrhea, amenorrhea
- MeSH terms
- Contraceptive Agents, Hormonal, Adult, Combined Modality Therapy, Endometriosis, Endometrium, Female, Humans, Middle Aged, Norpregnadienes, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ulipristal Acetate Prior to Surgery for Endometriosis. https://app.cochat.ai/papers/10.1007/s43032-020-00146-1
- The paper
- Singh, S. S., Evans, D., McDonald, S., Senterman, M., & Strickland, S. (2020). Ulipristal Acetate Prior to Surgery for Endometriosis. Reproductive Sciences. https://doi.org/10.1007/s43032-020-00146-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.